small molecule

EVRYSDI

RISDIPLAM

Loss of exclusivityApril 2041latest FDA-listed patent expiry

CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand name	EVRYSDI
Active ingredient	RISDIPLAM
Strength	5MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	February 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
12122789	April 2041	substance, product
11534444	October 2038	use U-1943
12350273	October 2038	use U-1943
11827646	January 2036	use U-1943
9969754	May 2035	substance, product
9586955	February 2033	substance, product

Regulatory exclusivity

Code	Expires
M-270	October 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Genentech